Abstract
The influence of the dopamine receptor blocking agent domperidone on prolactin and TSH secretion was studied in 16 infants, aged 10–360 days, who were treated for gastroesophageal reflux. The pretreatment serum prolactin levels were not statistically different from the levels in age-matched controls and showed the well-known inverse relationship with age. During treatment with domperidone a significant increase in prolactin level was observed on days 1, 4 and 21–28, the mean values on these three days not being statistically different. No correlation could be found between the serum prolactin levels and the corresponding plasma domperidone levels. One infant of this series and three not included in this series developed reversible breast hypertrophy with galactorrhoea in three of them: in none of them was the prolactin level, corrected for age, above 1 SD of the mean. All had received relatively high doses of domperidone. In 13 patients domperidone did not influence TSH secretion.
This is a preview of subscription content, log in via an institution to check access.
References
Albibi R, Dubovik S, Lange R, McCallum RW (1982) A dose response study of the effect of domperidone on gastric retention states in man. Am J Gastroenterol 77:679
Brugmans J (1981) Domperidone (R 33,812): an appraisal of the literature. In: Poster DS, Penta JS, Bruno S (eds) Treatment of cancer chemotherapy induced nausea and vomiting. Masson Publishing USA, New York, pp 177–193
Cann P, Read N, Holdsworth C (1983) Galactorrhea as side effect of domperidone. Br Med J 286:1395–1396
Clara R (1979) Chronic regurgitation and vomiting treated with domperidone (R 33 81): a multicenter evaluation. Acta Paediatr Belg 32:203–207
Delitala G, Devilla L, Lotti G (1980) Domperidone, an extracerebral inhibitor of dopamine receptors, stimulates thyrotropin and prolactin release in man. J Clin Endocrinol Metab 50:1127–1130
Grill B, Hillemever A, Semeraro L, McCallum R, Grybosky J (1985) Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastroesophageal reflux. j Pediatr 106:311–316
Guyda H, Friesen H (1973) Serum prolactin levels in humans from birth to adult life. Pediatr Res 7:534–540
Huizing G, Brouwers J, Westhuis P (1980) Plasma drug concentration and prolactin release after acute and subchronic oral administration of domperidone and metoclopramide. In: Merkus F (ed) The serum concentration of drugs. Excerpta Medica, Amsterdam, pp 271–277
Kaufman J, Elewaut A, Vermeulen A (1981) Effect of domperidone on prolactin (PRL) and thyrotropin (TSH) secretion. Arch Intern Pharmacodyn 254:293–303
Massara F, Camanni F, Amoroso A, Molinatti GM, Muller E (1981) Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects. Acta Endocrinol 97:48–53
Nagler J, Miskovitz P (1981) Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress. Am J Gastroenterol 76:495–499
Sol P, Pelet B, Guignard JP (1980) Extra pyramidal reactions due to domperidone. Lancet II:802
Sowers J, Sharp B, McCallum R (1982) Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J Clin Endocrinol Metab 54:869–871
Van Der Steen M, Du Caju M, Van Acker K (1982) Gynaecomastia in a male infant given domperidone. Lancet II:884–885
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deprettere, A.R., Van Acker, K.J. & Du Caju, M.V.L. Increased serum prolactin but normal TSH during prolonged domperidone treatment in children. Eur J Pediatr 146, 189–191 (1987). https://doi.org/10.1007/BF02343232
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02343232